Patents by Inventor Jianbin Wang

Jianbin Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10987317
    Abstract: The present invention relates to a method of reducing the production of glutamate from glutamine by glutaminase C in a cell or tissue. The method involves inhibiting glutaminase C activity in the cell or tissue under conditions effective to reduce production of glutamate from glutamine. Compounds for carrying out this method are also disclosed.
    Type: Grant
    Filed: January 13, 2020
    Date of Patent: April 27, 2021
    Assignee: Cornell University
    Inventors: Richard A. Cerione, Jon W. Erickson, Kristin Wilson Cerione, Jianbin Wang
  • Publication number: 20210070830
    Abstract: The present disclosure provides a system for regulating expression of a target polynucleotide in a cell. The system may comprise a chimeric polypeptide comprising a gene modulating polypeptide fused in-frame with a heterologous nuclear localization domain. The heterologous nuclear localization domain may be operable to translocate the chimeric polypeptide to a cell nucleus upon activation by an active cellular signaling pathway. The cellular signaling pathway may be inducible in response to an extracellular signal. In response to the extracellular signal, the chimeric polypeptide may localize to the cell nucleus and the gene modulating polypeptide may regulate expression of a target polynucleotide in the cell nucleus.
    Type: Application
    Filed: September 18, 2020
    Publication date: March 11, 2021
    Inventors: Pei-Qi LIU, Jianbin WANG
  • Publication number: 20200401410
    Abstract: An instruction execution method suitable for being executed by a processor is provided. The first processor comprises a register alias table (RAT) and a reservation station. The instruction execution method includes: a register alias table receives a first micro-instruction and a second micro-instruction and issues the first micro-instruction and the second micro-instruction to the reservation station; and the reservation station assigns one of a plurality of execution units to execute the first micro-instruction, according to the first specific message of the first micro-instruction; and the reservation station assigns one of the execution units to execute the second micro-instruction, according to the second specific message of the second micro-instruction.
    Type: Application
    Filed: March 10, 2020
    Publication date: December 24, 2020
    Inventors: Penghao ZOU, Chen-Chen SONG, Kang-Kang ZHANG, Jianbin WANG
  • Publication number: 20200299554
    Abstract: A method of preparing polyurethane hot melt adhesive with high temperature resistance generally includes the following steps: (1) adding isocyanate with a silane modifier in a reactor in an inert atmosphere, heating and stirring, then adding chemical dehydrant into the reactor and mixing evenly; (2) adding dehydrated diluent and tackifier resin to the reactor while maintaining the inert atmosphere and heating, adding dehydrated polyester polyol and polyether polyol, stirring, and allowing to react at constant temperature for a predetermined time period; (3) adding dehydrated polyether amine, stirring, and heating; and (4) adding a catalyst, vacuumizing, discharging materials and packaging the materials in an airtight container.
    Type: Application
    Filed: November 27, 2017
    Publication date: September 24, 2020
    Applicant: Yantai Darbond Technology Co.,Ltd.
    Inventors: Guilin JIANG, Jianbin WANG, Tianan CHEN, Haihua XIE
  • Patent number: 10781345
    Abstract: A method of preparing polyurethane hot melt adhesive with high temperature resistance generally includes the following steps: (1) adding isocyanate with a silane modifier in a reactor in an inert atmosphere, heating and stirring, then adding chemical dehydrant into the reactor and mixing evenly; (2) adding dehydrated diluent and tackifier resin to the reactor while maintaining the inert atmosphere and heating, adding dehydrated polyester polyol and polyether polyol, stirring, and allowing to react at constant temperature for a predetermined time period; (3) adding dehydrated polyether amine, stirring, and heating; and (4) adding a catalyst, vacuumizing, discharging materials and packaging the materials in an airtight container.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: September 22, 2020
    Assignee: Yantai Darbond Technology Co., Ltd.
    Inventors: Guilin Jiang, Jianbin Wang, Tianan Chen, Haihua Xie
  • Publication number: 20200277679
    Abstract: Disclosed herein are methods and compositions for generating a single-stranded break in a target sequence, which facilitates targeted integration of one or more exogenous sequences.
    Type: Application
    Filed: May 15, 2020
    Publication date: September 3, 2020
    Inventor: Jianbin Wang
  • Patent number: 10689717
    Abstract: Disclosed herein are methods and compositions for generating a single-stranded break in a target sequence, which facilitates targeted integration of one or more exogenous sequences.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: June 23, 2020
    Assignee: Sangamo Therapeutics, Inc.
    Inventor: Jianbin Wang
  • Publication number: 20200157534
    Abstract: The present disclosure provides systems, methods, and compositions for conditionally regulating expression of a target gene. Aspects of the present disclosure utilize intracellular signal transduction pathways to regulate the expression of a gene (e.g., transgene, exogenous gene, endogenous gene).
    Type: Application
    Filed: January 10, 2020
    Publication date: May 21, 2020
    Inventors: Jianbin WANG, Bing WANG, Pei-Qi LIU
  • Patent number: 10532034
    Abstract: The present invention relates to a method of reducing the production of glutamate from glutamine by glutaminase C in a cell or tissue. The method involves inhibiting glutaminase C activity in the cell or tissue under conditions effective to reduce production of glutamate from glutamine. Compounds for carrying out this method are also disclosed and include those of formula (III): wherein B, R1c, R2c, m, and n are defined herein.
    Type: Grant
    Filed: March 25, 2010
    Date of Patent: January 14, 2020
    Assignee: Cornell University
    Inventors: Richard A. Cerione, Jon W. Erickson, Kristin Wilson Cerione, Jianbin Wang
  • Patent number: 10494648
    Abstract: The present disclosure is in the field of genome engineering, particularly targeted modification of the genome of a cell.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: December 3, 2019
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Michael C. Holmes, Jianbin Wang
  • Publication number: 20190224284
    Abstract: Herpes simplex virus (HSV) including herpes simplex virus 1 and 2 (HSV-1 and HSV-2) are a persistent cause of human disease with no known cure. Guided nuclease systems target specific regions of the HSV-1 and HSV-2 genomes, disrupting the virus' nucleic acid and rendering even latent viruses incapacitated.
    Type: Application
    Filed: September 5, 2018
    Publication date: July 25, 2019
    Inventors: Stephen R. Quake, Jianbin Wang
  • Publication number: 20190201501
    Abstract: The invention provides compositions and methods for treating human papillomavirus (HPV) infections using a targetable nuclease, which compositions and methods can be used to selectively target the HPV genome or selectively express the targetable nuclease within cells that infected by HPV. By selectively targeting cells infected by HPV, the HPV genome within infected cells, or both, the nuclease is able to cleave the HPV genome thereby inactivating it and rendering it inoperable, interfering with the virus's ability to propagate even where the virus is in a latent stage of infection. Since latent HPV can be cleaved and eradicated from the host cells, compositions and methods of the invention may be used to treat HPV infections and potentially prevent many of the adverse health consequences associated with the papillomavirus.
    Type: Application
    Filed: December 18, 2018
    Publication date: July 4, 2019
    Inventors: Stephen R. Quake, Jianbin Wang
  • Publication number: 20190185882
    Abstract: The invention provides delivery methods and compositions for antiviral therapeutics. Methods and compositions are provided for targeted delivery of antiviral therapeutics into cells of interest using, for example, viral vectors such as adenovirus, AAV, and replication incompetent HSV. These and other delivery systems can be used as vehicles to deliver DNA vectors encoding a nuclease or a cell-killing gene. These delivery methods can also be used to deliver naked DNA or RNA, protein products, plasmids containing a promoter that is active only in a latent viral state which drives a cell-killing gene, or other therapeutic agents.
    Type: Application
    Filed: July 26, 2018
    Publication date: June 20, 2019
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Stephen R. Quake, Jianbin Wang
  • Patent number: 10196652
    Abstract: Methods and compositions comprising a CRISPR/Cas nuclease that cleaves a T cell receptor (TCR) gene and/or human leukocyte (HLA) gene, the nuclease comprising a cleavage domain and a single guide RNA that binds to a target site in the TCR and/or HLA gene.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: February 5, 2019
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Anthony Conway, Gregory J. Cost, Russell Dekelver, Edward J. Rebar, Andreas Reik, Fyodor Urnov, Jianbin Wang, H. Steve Zhang
  • Patent number: 10196651
    Abstract: Methods and compositions comprising a CRISPR/Cas nuclease that cleaves a BCL11A gene for the modification of the BCL11A gene and for modification of globin expression.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: February 5, 2019
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Anthony Conway, Gregory J. Cost, Russell Dekelver, Edward J. Rebar, Andreas Reik, Fyodor Urnov, Jianbin Wang, H. Steve Zhang
  • Publication number: 20190032158
    Abstract: Disclosed herein are methods and compositions for generating a single-stranded break in a target sequence, which facilitates targeted integration of one or more exogenous sequences.
    Type: Application
    Filed: September 28, 2018
    Publication date: January 31, 2019
    Inventor: Jianbin Wang
  • Publication number: 20190032090
    Abstract: Viral infection is a persistent cause of human disease. Guided nuclease systems target the genomes of viral infections, rendering the viruses incapacitated.
    Type: Application
    Filed: March 20, 2018
    Publication date: January 31, 2019
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Stephen R. Quake, Jianbin Wang
  • Publication number: 20190010518
    Abstract: Viral infection is a persistent cause of human disease. Guided nuclease systems of the invention target the genomes of viral infections, rendering the viruses incapacitated. The invention further provides delivery methods and compositions for antiviral therapeutics. Methods and compositions are provided for targeted delivery of antiviral therapeutics into cells of interest using, for example, viral vectors such as adenovirus, AAV, and replication incompetent HSV. These and other delivery systems can be used as vehicles to deliver DNA vectors encoding a nuclease or a cell-killing gene. These delivery methods can also be used to deliver naked DNA or RNA, protein products, plasmids containing a promoter that is active only in a latent viral state which drives a cell-killing gene, or other therapeutic agents.
    Type: Application
    Filed: January 23, 2018
    Publication date: January 10, 2019
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Stephen R. Quake, Jianbin Wang
  • Patent number: 10140128
    Abstract: A parallelized multiple dispatch ordered queue including an ordered queue, qualify logic, ordered select logic, and dispatch logic. The ordered queue stores candidates in order from oldest to youngest into multiple entries. The ordered queue is divided into N groups in which an i'th group includes every i'th entry of every N entries of the ordered queue, wherein i is an integer less than or equal to N. The qualify logic determines whether any candidate is ready to be dispatched. The ordered select logic respectively determines the oldest candidate in each group that is ready to be dispatched. The dispatch logic dispatches the oldest ready candidates in parallel. The shift logic shifts the stored candidates in the ordered queue to fill any vacant entries between remaining ones of the stored candidates without changing an order of the remaining ones of the stored candidates in the ordered queue. The ordered queue may have any size or depth and N is any suitable integer determining the number of candidates (e.g.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: November 27, 2018
    Assignee: VIA ALLIANCE SEMICONDUCTOR CO., LTD.
    Inventors: Qianli Di, Jianbin Wang, Weili Li, Xiaoyuan Yu, Xin Yu Gao
  • Patent number: 10117911
    Abstract: Herpes simplex virus (HSV) including herpes simplex virus 1 and 2 (HSV-1 and HSV-2) are a persistent cause of human disease with no known cure. Guided nuclease systems target specific regions of the HSV-1 and HSV-2 genomes, disrupting the virus' nucleic acid and rendering even latent viruses incapacitated.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: November 6, 2018
    Assignee: Agenovir Corporation
    Inventors: Stephen R. Quake, Jianbin Wang